Avid Bioservices Inc (CDMO)

[freethemice]

I wrote an e-mail previously in which I had presented a much better comparison trial for
the old phase 2a first-line NSCLC trial instead of using the Avastin + CP first-line trial,
as done by Peregrine in their PR. This shows that an increase in MOS of 40-50% is reasonable
for the current phase 2b first-line NSCLC, assuming the control and treatment arms are balanced.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83747030